Apellis Pharmaceuticals
Focus: Apellis is a specialty pharmaceutical company focused on complement inhibitors, with a concentrated commercial portfolio anchored by EMPAVELI and SYFOVRE for rare complement-mediated diseases. The company operates from Australia with a lean 12-person active hiring footprint.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Open Jobs
12-9 this month
Cooling — net -9 jobs in 30d
3 added, 12 removed. Slower than typical.
Should You Work at Apellis Pharmaceuticals?
AI assessmentBest fit for specialists seeking rare disease commercialization or complement biology expertise; riskier for those seeking stability or broad career optionality.
Why Work Here
- Lead on a marketed asset at peak commercial stage with strong Part D reimbursement ($25M EMPAVELI, $2M SYFOVRE)
- Rare disease focus with dedicated complement inhibitor platform offering deep scientific specialization
Data completeness
6/9 — Partial
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
Help build intelligence for Apellis Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.